Skip to main content

The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.

Publication ,  Journal Article
Fryml, LD; Williams, KR; Pelic, CG; Fox, J; Sahlem, G; Robert, S; Revuelta, GJ; Short, EB
Published in: J Psychiatr Pract
May 2017

Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome. For reasons that are not entirely understood, abrupt changes in amantadine dosage can produce a severe withdrawal syndrome. Existing medical literature describes case reports of amantadine withdrawal leading to delirium, which at times has progressed to neuroleptic malignant syndrome. Amantadine withdrawal may be under-recognized by mental health clinicians, which has the potential to lead to protracted hospital courses and suboptimal outcomes. The goal of this case series is to highlight the role of amantadine withdrawal in the cases of 3 medically complex patients with altered mental status. In the first case, the cognitive side effects of electroconvulsive therapy masked acute amantadine withdrawal in a 64-year-old man with Parkinson disease. In the second case, a 75-year-old depressed patient developed a catatonic delirium when amantadine was discontinued. Finally, a refractory case of neuroleptic malignant syndrome in a 57-year-old patient with schizoaffective disorder rapidly resolved with the reintroduction of outpatient amantadine. These cases highlight several learning objectives regarding amantadine withdrawal syndrome: First, it may be concealed by co-occurring causes of delirium in medically complex patients. Second, its symptoms are likely to be related to a cortical and limbic dopamine shortage, which may be reversed with electroconvulsive therapy or reintroduction of amantadine. Third, its clinical presentation may occur on a spectrum and may include features suggestive of delirium, catatonia, or neuroleptic malignant syndrome.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Psychiatr Pract

DOI

EISSN

1538-1145

Publication Date

May 2017

Volume

23

Issue

3

Start / End Page

191 / 199

Location

United States

Related Subject Headings

  • Substance Withdrawal Syndrome
  • Psychotic Disorders
  • Psychiatry
  • Neuroleptic Malignant Syndrome
  • Middle Aged
  • Male
  • Humans
  • Electroconvulsive Therapy
  • Dopamine Agents
  • Delirium
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fryml, L. D., Williams, K. R., Pelic, C. G., Fox, J., Sahlem, G., Robert, S., … Short, E. B. (2017). The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract, 23(3), 191–199. https://doi.org/10.1097/PRA.0000000000000237
Fryml, Leah D., Kristen R. Williams, Christopher G. Pelic, James Fox, Gregory Sahlem, Sophie Robert, Gonzalo J. Revuelta, and Edward Baron Short. “The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.J Psychiatr Pract 23, no. 3 (May 2017): 191–99. https://doi.org/10.1097/PRA.0000000000000237.
Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, et al. The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract. 2017 May;23(3):191–9.
Fryml, Leah D., et al. “The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.J Psychiatr Pract, vol. 23, no. 3, May 2017, pp. 191–99. Pubmed, doi:10.1097/PRA.0000000000000237.
Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, Revuelta GJ, Short EB. The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract. 2017 May;23(3):191–199.

Published In

J Psychiatr Pract

DOI

EISSN

1538-1145

Publication Date

May 2017

Volume

23

Issue

3

Start / End Page

191 / 199

Location

United States

Related Subject Headings

  • Substance Withdrawal Syndrome
  • Psychotic Disorders
  • Psychiatry
  • Neuroleptic Malignant Syndrome
  • Middle Aged
  • Male
  • Humans
  • Electroconvulsive Therapy
  • Dopamine Agents
  • Delirium